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Abstract
Background: Enlargement of the prostate is associated with prostatic diseases in dogs, and an estimation of
prostatic size is a central part in the diagnostic workup. Ultrasonography is often the method of choice, but
biomarkers constitute an alternative. Canine prostate specific esterase (CPSE) shares many characteristics with
human prostate specific antigen (PSA) and is related to prostate size. In men with clinical symptoms of prostatic
disease, PSA concentrations are related to prostate growth. The aims of the present follow-up study were to
evaluate if the concentration of CPSE is associated with future growth of the prostate, and if analysis of a panel of
16 steroids gives further information on prostatic growth. Owners of dogs included in a previous study were 3
years later contacted for a follow-up study that included an interview and a clinical examination. The prostate was
examined by ultrasonography. Serum concentrations of CPSE were measured, as was a panel of steroids.
Results: Of the 79 dogs included at baseline, owners of 77 dogs (97%) were reached for an interview, and 22 were
available for a follow-up examination. Six of the 79 dogs had clinical signs of prostatic disease at baseline, and eight
of the remaining 73 dogs (11%) developed clinical signs between baseline and follow-up, information was lacking
for two dogs. Development of clinical signs was significantly more common in dogs with a relative prostate size of
≥2.5 at baseline (n = 20) than in dogs with smaller prostates (n = 51). Serum concentrations of CPSE at baseline
were not associated with the change in prostatic size between baseline and follow-up. Serum concentrations of
CPSE at baseline and at follow-up were positively associated with the relative prostatic size (Srel) at follow-up.
Concentrations of corticosterone (P = 0.024), and the class corticosteroids (P = 0.0035) were positively associated
with the difference in Srel between baseline and follow-up.
Conclusions: The results support the use of CPSE for estimating present and future prostatic size in dogs ≥4 years,
and the clinical usefulness of prostatic size for predicting development of clinical signs of prostatic disease in the
dog. The association between corticosteroids and prostate growth warrants further investigation.
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Background
The prostate is an androgen-dependent gland. In intact
middle-aged and old dogs, an enlarged prostate is a nat-
ural sequel to androgen production, and with age almost
all will develop benign prostatic hyperplasia (BPH) [1–
3]. The type of hyperplasia varies with age, from a glan-
dular hyperplasia in younger dogs to a complex form
with glandular hyperplasia, increased amount of stroma,
often cystic alveoli and chronic inflammation in older
dogs [1, 2]. The prostate growth is more pronounced
during the first 4 years and then reaches a plateau [2].
After 4 years, a correlation between the size and age is
not always evident [4], and in senior dogs, an involution
may occur [5]. Although growth is androgen dependent,
it is not related to increasing testosterone concentra-
tions. Instead, a mild decrease in serum testosterone
concentrations is seen with increasing age, while con-
centrations of estrogens remain similar or increase [3,
6]. As a consequence, the testosterone/estradiol relation-
ship has been described as a measurable indicator of
BPH [7]. In men, both estrogen receptor (ER) α and β
have been described to be more strongly expressed in
epithelial cells of hyperplastic than of normal prostates
[8]. Beside a decreased androgen/estrogen ratio, several
other factors, including stromal growth factors and
chronic inflammation, have been indicated to play a role
in the pathogenesis of BPH [9].
Although most, if not all, intact males will develop
BPH with time, only a sub-population will show related
clinical signs, often associated with a prostate that is
markedly increased in size [10]. Signs related to BPH in-
clude ribbon-like stools [11], hematuria, incontinence
and tenesmus [12]. The sperm quality may be affected
leading to fertility problems [13]. Clinical signs may be
insidious in nature, and, at least initially, go unnoticed
by owners [4]. The fact that many male dogs have subtle
signs of BPH, and veterinary care may not be sought
until the signs have become severe, makes BPH a poten-
tial welfare problem in the ageing male. In addition,
presence of BPH increases the risk of developing other
prostate diseases, mainly prostatitis, a condition that
may be life-threatening [12].
Because BPH and most other prostatic diseases are as-
sociated with an enlargement of the prostate, estimation
of prostatic size is a central part in the diagnostic
workup. Rectal palpation is a quick and easy first step
[14], although not always feasible in larger dogs, or in
older dogs, as the position of the prostate often changes
with age from the pelvic to the abdominal cavity, and
ultrasonography is often the method of choice [15, 16].
An ultrasound examination not only gives information
on size, but also on shape, contour, echogenicity and
symmetry, and it also adds information on adjacent soft
tissue [17]. The drawback is related to availability of
equipment and skill of the veterinarian performing the
investigation. An alternative for estimating an increased
prostatic size is analysis of serum concentration of the
biomarker canine prostate specific esterase (CPSE) [4].
CPSE is an arginine esterase, and the major secretory
product of the canine prostate [18]. Serum CPSE con-
centrations are significantly higher in dogs with BPH
than in normal dogs [7, 19, 20]. Several authors have
suggested inclusion of CPSE analysis in the diagnostic
workup of dogs with clinical signs of BPH, and for
screening of geriatric dogs [4, 21, 22]. There are several
similarities between CPSE in dogs and prostate specific
antigen (PSA) in men. Both are serine proteases with
similar regulation [18, 23]. In men, it has been described
that the concentrations of PSA may predict the future
growth of the prostate gland [24]. If this would be the
case also for CPSE in dogs, the diagnostic value of a
CPSE analysis would increase further.
The aims of the present follow-up study were to evalu-
ate if the concentration of CPSE is associated with future
growth of the prostate, and if analysis of a panel of 16
steroids gives further information on prostatic growth.
Results
The number of dogs included in the different parts of
the study is summarized in Fig. 1.
Interview
Of 79 dogs included at baseline, six dogs had clinical
signs of prostatic disease and 73 dogs had no such clin-
ical signs. Contact was established with owners of 77
dogs (97%). The interviews revealed that in addition to
the six dogs with clinical signs at inclusion, eight dogs
(8/73, 11%) had developed clinical signs of prostatic
disease since baseline, the most common being haema-
turia, urinary incontinence and tenesmus. The median
baseline concentration of CPSE for dogs that later devel-
oped clinical signs was 135 ng/ml (interquartile range,
IQR 71–402 ng/ml), and for dogs that did not develop
clinical signs 61 ng/ml (IQR < 25 to 130 ng/ml). The
difference between these groups was not significant (P =
0.1). Dogs with a Srel of ≥2.5 at baseline (n = 20) had
significantly more often than those with a smaller Srel
(n = 51) developed clinical signs of prostatic disease (P =
0.035). Information from two dogs was lacking. Median
(IQR) Srel at baseline was 3.0 (1.7–3.5) for dogs that had
developed clinical signs and 1.8 (1.3–2.4) for dogs that
had not developed clinical signs.
Of the 79 dogs that were included at baseline, 22
(28%) were available for a follow-up examination. Rea-
sons for not participating in the follow-up were for the
other 57 dogs euthanasia (n = 25), surgical castration
(n = 8), treatment with osaterone acetate (n = 7), long
distance (n = 7), treatment with deslorelin (n = 6), no
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answer (n = 2), treatment with both osaterone acetate
and deslorelin (n = 1), or was not interested in participat-
ing (n = 1). The most common causes for euthanasia
were neoplasia (n = 11), multifactorial (n = 5), age (n = 4),
and joint problems (n = 4).
Ultrasonography, CPSE and steroid concentration
Of the 22 dogs available for follow-up, 21 did not have
signs of prostatic disease. One Rottweiler had a sanguin-
eous urethral discharge that was evident when in contact
with bitches in heat. The Srel of his prostate was 2.9, and
had not changed significantly since baseline. He had > 5
intra-prostatic cysts at follow-up.
The 22 dogs were of 14 different breeds. Their median
age and weight at baseline were 5.2 years (IQR 4.0–7.0)
and 27.8 kg (IQR 12.5–37.5), respectively. At follow-up,
their median age was 8.8 years (IQR 7–10.3) and median
weight was 26.3 kg (IQR 13.8–37.7). At baseline, 27% of
these 22 dogs had prostates with a relative size ≥2.5, and
at follow-up this proportion was 41%.
The V and Srel had increased slightly but significantly
from baseline to follow-up (P = 0.006, Table 1). The
volume had increased in 12 dogs (median age 9.5 years
(IQR 8.0–11.8), median CPSE concentration at baseline
59.1 ng/ml (IQR 15.4–111.0)). For nine dogs, volume
had changed less than 15%. Their median age was 7
years (IQR 7.0–8.8), median CPSE concentration at
baseline 47 ng/ml (28.1–77.0). The volume of the pros-
tate had decreased 27% in one 13-year-old dog with
CPSE at baseline 95 ng/ml. The change in Srel between
baseline and follow-up in individual dogs is shown in
Fig. 2.
Using multiple regression, baseline CPSE concentra-
tions and concentrations at follow-up were significantly
Fig. 1 Chart of the study design with number of dogs included in the different steps
Table 1 Serum concentration of CPSE, size of the prostate, and
dogs with presence of cysts at baseline and follow-up (n = 22)
Parameter Baseline Follow-up P-value
CPSE, ng/ml Median (IQR) 52 (24–97) 107 (49–416) 0.001
V, cm3 Median (IQR) 18 (12–30) 21 (15–38) 0.006
Srel Median (IQR) 1.8 (1.2–2.2) 2.2 (1.4–2.9) 0.006
Cysts, presence N (%) 12 (54) 18 (82) 0.18
CPSE canine prostate specific esterase, V Volume of the prostate, Srel relative
size of the prostate, Cysts prostatic cysts
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associated with Srel at follow-up (Table 2). The Pearson
correlation coefficient (r) between baseline CPSE and
Srel at follow up was 0.53 (P = 0.011). Age and weight
were not significantly associated with Srel at follow-up.
None of the steroids, analyzed separately, as classes or as
ratios, were significantly associated with the Srel at
follow-up. One steroid, corticosterone was associated
with the difference in Srel between baseline and follow-
up (regression coefficient 0.5, adjusted R2 = 0.75, P =
0.024), as was the class corticosteroids (regression coeffi-
cient 0.008, adjusted R2 = 0.34, P = 0.003). Median con-
centrations of steroids in dogs with different Srel are
presented in Table 3.
The shape of the prostate was symmetrical both at
baseline and at follow-up in 17 dogs. It changed from
asymmetrical to symmetrical in two dogs and from sym-
metrical to asymmetrical in three dogs. The contour
remained smooth in all dogs. The parenchyma did not
change for 17 dogs; seven with a homogenous and 10
with heterogeneous echogenicity. It changed to hetero-
geneous in four dogs and to homogeneous in one dog.
At baseline, 12 dogs (54%) had prostatic cysts, all with
one to five cysts. At follow-up, 18 dogs (82%) had
detectable cysts: five had one to five cysts as previously,
and five had an increased number of cysts (> 5) com-
pared to baseline. Of 10 dogs that did not have any cysts
at baseline, eight had developed one to five cysts at
follow-up.
Discussion
Circulating biomarkers for the evaluation of the canine
prostate are valuable for the practicing veterinarian with
limited access to an ultrasound equipment. Concentra-
tions of CPSE are related to the size of the prostate [4]
and to the presence of BPH [7, 19, 20]. The analysis of
CPSE can therefore contribute with important informa-
tion both in the workup of cases with clinical signs re-
lated to the prostate, and in the screening panel for old
male dogs. The samples must be taken after a proper
sexual rest, as ejaculation increases the CPSE concentra-
tion in serum [25]. We have previously described that
clinical signs were more common in dogs with a Srel of
≥2.5, with a CPSE concentration of ≥90 ng/ml [4]. In the
present study, dogs with a baseline Srel ≥ 2.5 significantly
more often had developed clinical signs of prostatic dis-
ease at follow-up than those with smaller Srel. This
supports the clinical usefulness of this cut-off. The con-
centrations of CPSE did not differ between dogs that
had developed clinical signs and those that had not done
so. We have previously described an association between
CPSE concentrations and size of the prostate [4], and
the lack of association between CPSE concentrations
Fig. 2 Change in relative size, Srel, of the prostate between baseline and follow-up, in dogs (n = 22) of various ages
Table 2 Association between CPSE concentration at baseline and follow-up, and relative prostatic size at follow-up, adjusted R2 = 0.51
Parameter Regression coefficient Standard Error t-value P-value
CPSE baseline 0.005 0.0016 3.3 0.004
CPSE follow-up 0.003 0.00079 3.5 0.003
CPSE canine prostate specific esterase
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Table 3 Concentration of the different steroids, classes of steroids, ratios of classes of steroids and of canine prostate specific
esterase (CPSE) in dogs at follow-up
Steroid Prostatic size N Median (ng/ml) IQR
Aldosterone < 2.5 13 0.10 0.04–0.31
≥2.5 9 0.26 0.17–0.44
Androsterone < 2.5 13 0.069 0.04–0.16
≥2.5 9 0.041 0.01–0.15
Androstenedione < 2.5 13 1.43 0.4–2.16
≥2.5 9 2.20 1.2–3.4
Cortisol < 2.5 13 36.7 17.3–58.6
≥2.5 9 21.5 14.5–38.9
Cortisone < 2.5 13 14.75 10.4–20.32
≥2.5 9 10.41 7.5–23.60
Corticosterone < 2.5 13 1.81 1.2–3.77
≥2.5 9 1.38 0.7–2.61
11-Deoxycorticosterone < 2.5 13 0.40 0.13–0.79
≥2.5 9 0.17 0.076–0.31
11-Deoxycortisol < 2.5 13 6.82 4.2–8.39
≥2.5 9 4.86 1.96–8.29
DHEA < 2.5 13 0.63 0.34–2.53
≥2.5 9 1.56 0.58–2.32
Etiocholanolone < 2.5 13 0.24 0.18–0.32
≥2.5 9 0.34 0.29–0.44
17α-hydroxyprogesterone < 2.5 13 0.11 0.079–0.22
≥2.5 9 0.14 0.070–0.21
Pregnanolone < 2.5 13 0.46 0.34–0.60
≥2.5 9 0.46 0.39–0.54
Progesterone < 2.5 13 0.14 0.078–0.29
≥2.5 9 0.14 0.065–0.22
Testosterone < 2.5 13 1.40 0.98–3.30
≥2.5 9 2.41 2.17–4.59
Estrone < 2.5 13 0.023 0.0004–0.05
≥2.5 9 0.036 0.013–0.059
Estradiol < 2.5 13 0.0072 0.00–0.017
≥2.5 9 0.0075 0.00–0.016
CPSE (follow-up) < 2.5 13 83.0 29.6–118.4
≥2.5 9 153.3 91.8–550.2
SUM estrogens < 2.5 13 0.039 0.0069–0.059
≥2.5 9 0.036 0.021–0.078
SUM androgens < 2.5 13 3.45 2.11–8.5
≥2.5 9 9.13 4.45–11.6
SUM corticosteroids < 2.5 13 57.43 43.36–91.21
≥2.5 9 39.6 28.3–71.0
SUM progestins < 2.5 13 0.79 0.602–1.01
≥2.5 9 0.69 0.625–1.074
Androgens/estrogens < 2.5 11 140 87–301
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and development of clinical signs in the present study
may be due to the relatively small study population, with
eight of 73 dogs developing clinical signs.
Concentrations of PSA in men with moderate to se-
vere clinical signs and an enlarged prostate have been
described to predict prostate growth [24]. The PSA ana-
lysis thus contributes with specific information in this
group of patients. In the present study, CPSE concentra-
tions at baseline were significantly correlated with Srel at
follow up. The concentration of CPSE is thus not only
correlated with present prostatic size, but also with the
future size. However, although CPSE is similar to PSA,
there was no association between baseline CPSE concen-
trations and the difference in Srel between baseline and
follow-up. The study population of dogs differed from
the study in men in that most dogs were without clinical
signs, and not all had enlarged prostates. It may there-
fore be that an association between CPSE and difference
in Srel would have been detected with a different study
population, including only dogs with enlarged prostates
and clinical signs, or with a larger study population.
In the present study, 11% of the dogs from the baseline
study with owners that were interviewed had, according
to their owners, developed clinical signs of prostatic dis-
ease during the 3-year-period after the examination at
baseline. These results highlight that clinical signs re-
lated to the prostate are common in intact male dogs >
4 years. When included in the study at baseline, these
dog owners became aware of prostatic diseases, and this
awareness, together with the fact that all dogs were > 4
years old, may have contributed to this relatively high
proportion of dogs with clinical signs.
In a previous study on dogs registered in a teaching
veterinary hospital database, 0.7% had prostatic disorders
[26]. This much lower number is likely influenced by the
age distribution. It has previously been described that a
large proportion of visits to an animal hospital consists
of young dogs [27]. Another contributing factor is likely
a proportion of castrated dogs, and another breed distri-
bution, as the prevalence of prostatic disease differs be-
tween different breeds and sizes of dogs [26]. Clinical
signs of prostatic disease may be insidious and may not
lead to a visit at a veterinarian [4]. A low awareness of
prostatic disease among general dog owners indicates
that dogs getting veterinary care for this condition are
only the tip of an iceberg. Due to this, many male dogs
may suffer unnecessarily from a curable condition. Pre-
vention screening of the prostate of male dogs has been
recommended [4, 28], and is supported by the present
study. The present results also point to the education of
dog owners on the clinical signs of prostate disease, and
possibilities for treatment, as a means to increase health
and welfare of male dogs.
Despite the relationship between BPH and size of the
prostate, and between prostate size and clinical signs, it
should be noted that although 41% of the dogs at
follow-up had Srel > 2.5, only one of them (4%) had clin-
ical signs of prostatic disease. In men, prostate size cor-
relates poorly with clinical signs [29], indicating that
other factors contribute. One such factor is prostatic fi-
brosis that is related to clinical signs in men [30]. Colla-
gen structure in prostates of dogs and men is similar
[31]. The majority of collagen is localized to the pros-
tatic urethra, and a dense collagen network is present in
capsular regions. Older, intact dogs have denser collagen
fibers and thicker capsular fibers than young, intact
males [31]. The presence of urinary signs in male dogs
may thus be related to fibrosis, as in men. In men, the
prostate has different zones, with BPH occurring more
commonly in the transitional zone, surrounding the ur-
ethra [32], which is one reason for signs not being dir-
ectly related to the overall size of the prostate. The
canine prostate does not have different zones, and glan-
dular proliferation occurs in all portions of the gland [1,
Table 3 Concentration of the different steroids, classes of steroids, ratios of classes of steroids and of canine prostate specific
esterase (CPSE) in dogs at follow-up (Continued)
Steroid Prostatic size N Median (ng/ml) IQR
≥2.5 9 202.5 96.2–481.9
Progestins/estrogens < 2.5 11 23.4 11.6–31.6
≥2.5 9 23.05 9.64–30.66
Corticosteroids/estrogens < 2.5 11 1838 619–3710
≥2.5 9 1127 392–5148
Androgens/progestins < 2.5 13 5.44 2.5–11.27
≥2.5 9 8.34 7.27–16.47
Corticosteroids/androgens < 2.5 13 19.18 6.44–28.19
≥2.5 9 5.66 3.33–10.50
Corticosteroids/progestins < 2.5 13 84.6 44.6–104.5
≥2.5 9 63.1 40.2–100.3
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15]. However, more nodular changes may be present,
and cysts more common, in the periurethral area [1]. In
older dogs, when the hyperplasia commonly is of the
complex type, the presence of cysts in this area may be
related to blood-tinged discharges.
During the 3 years between baseline and follow-up, Srel
of the prostate had increased significantly. This is in ac-
cordance with previous studies showing that the prostate
gland increases in size with age in intact males [1, 2].
However, the median increase was rather low. The same
pattern was not seen in all dogs, and in 45% of the dogs,
the prostate had remained similar in size, or even de-
creased. The decrease in Srel in one dog may be caused
by senile involution [5] and the proportion with similar
Srel likely represents the plateau after 4 years, described
previously [2]. Not only the Srel increased between base-
line and follow-up, so did the proportion of dogs with
cysts, although not significantly. At baseline all dogs
with cysts had only few cysts, but at follow-up five of the
18 dogs with cysts had more than five cysts. The shape
of the prostate was symmetrical both at baseline and at
follow-up in 77% of the dogs. The presence of prostatic
cysts is typical for the complex form of BPH, dominating
from 7 years of age in beagles [1].
The pathogenesis behind BPH is complex, and modifi-
able as well as non-modifiable risk factors are suggested
in men, including inflammation, growth factors and
endocrine factors [9, 33]. A role for steroids in the devel-
opment of BPH has been indicated since long. Acinar
basal cells in the canine prostate are the major prolifera-
tive cell type, and express the androgen receptor [34],
and BPH is an androgen-dependent condition. However,
although the prevalence of BPH increases with age, tes-
tosterone concentrations tend to decrease [3]. In the
present study, we used SFC-MS/MS to evaluate the con-
centration of 16 steroids in relation to the size of the
prostate. The advantage with this method is the possibil-
ity to identify and quantify a large number of steroids
within a short time using a small sample volume. Panels
of steroids, and ratios between them, have been de-
scribed to potentially have advantages in personalized
medicine for men with prostatic cancer [35]. In the
present study, no single steroid, class of steroids or ratio
between different classes were associated with Srel at
follow-up. The disadvantage of this study is the relatively
low number of dogs included in this analysis, leading to
reduced power, which may be one explanation for this
lack of significant associations. Corticosterone and the
class corticosteroids were positively associated with the
difference in Srel between baseline and follow-up. The
association between the difference in Srel and corticoids
is interesting. Chronic stress activates the hypothalamic-
pituitary-adrenal axis, leading to increased concentra-
tions of corticosteroids and inflammatory responses, and
inflammation has been suggested as a contributing factor
to BPH [33]. However, corticosterone is not a primary
corticosteroid in dogs, and the results should therefore
be interpreted with caution. Further studies are required
before any conclusions can be drawn on the relationship
between stress and BPH in dogs.
Although owners of 97% of the dogs that were in-
cluded at baseline were reached for interviews, only 28%
of the dogs were available for a clinical follow-up. A gen-
eral problem with follow-up studies of conditions affect-
ing middle-aged or older dogs is that a proportion of
them will be euthanized or treated so that they have to
be excluded. In the present study, 32% had been eutha-
nized, many from tumours or joint disease, previously
described common causes of mortality [36]. Twenty-
eight per cent of the dogs included at baseline were ex-
cluded because of the exclusion criteria; surgical or med-
ical castration, or treatment for prostatic disease. Only
one dog owner expressed no interest in participating in
the clinical follow-up. The included dogs can therefore
be considered representative for intact male dogs that
have not been treated for prostatic disease.
Conclusion
CPSE concentrations at baseline and follow-up are sig-
nificantly associated with Srel at follow-up but not with
the difference in Srel between baseline and follow-up.
Corticosteroids, and specifically corticosterone, were as-
sociated with the difference in Srel between baseline and
follow-up. Dogs with a baseline Srel ≥ 2.5 were signifi-
cantly more likely to develop clinical signs of prostatic
disease than other dogs. Clinical signs had developed in




Owners to dogs included in a previous study [4] were
contacted and asked if they were willing to participate in
a follow-up. The follow-up included an interview and a
clinical study. In the clinical study, breed, age, and
weight were recorded, as was information on clinical
signs of possible prostatic disease. Ultrasonography of
the prostate was performed at one of the two animal
hospitals and two animal clinics that participated in the
original study. A venous blood sample was collected for
analysis of CPSE and steroid hormones.
Interview
Owners were contacted via phone (Additional file 1).
Questions included if the dog was still alive, and if it was
or had been treated for prostatic problems. The owners
were also asked if the dog had been surgically castrated
or if it was treated with deslorelin. If the dog was not
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alive, the owner was questioned about the reason for
euthanasia.
Inclusion and exclusion criteria for clinical part
Inclusion criteria were male dogs that had been included
in the previous study (baseline) [4]. Exclusion criteria
were treatment for prostatic disease or castrated since
baseline (3 years earlier).
Ultrasonography
The prostate was examined using the previously de-
scribed standardized protocol [4] by experienced veterin-
ary surgeons that had adequate equipment1. Transducer
type and frequency were optimized for the individual
dog to cover the entire prostate for measurements and
to get as good detail resolution as possible for the paren-
chymal evaluation.
Length, width, and height of the prostate were mea-
sured three times on different still images and the mean
values were used in further calculations. The prostatic
volume (V) for the individual dog was calculated accord-
ing to Kamolpatana et al. as V = (1/2.6) * (Length *
Width * Height) + 1.8 cm3 [16]. In addition prostatic par-
enchyma (homogenous or heterogenous), contour
(smooth or uneven); shape (symmetrical or asymmet-
rical), and presence of cysts (none, 1–5 or > 5) were
recorded.
Analysis of CPSE
Venous blood samples were collected and serum was
stored at − 70 °C until CPSE was analyzed using a com-
mercial ELISA; Odelis® CPSE (Virbac). Intra assay coeffi-
cient of variation (CV) was < 5% and interassay CV was
< 7%, according to the manufacturer. Samples with con-
centrations ≥200 ng/mL were diluted 1:10 and re-
analyzed.
Analysis of steroid hormones
An analysis of steroid hormones was performed by
supercritical fluid chromatography–tandem mass spec-
trometry (SFC–MS/MS, Waters Corporation, Milford,
MA, USA) system [37]. A slightly modified method of li-
quid -liquid extraction was used [37]. In brief, a 50 μL of
plasma was spiked with 50 μL mixture of a correspond-
ing deuterated internal standard mixture (10 μg/mL).
The protein precipitation was achieved by the addition
of 100 μL of ice cooled MeOH and followed by the
addition of 200 μL of MTBE, then vortexed for 15 min.
Samples were centrifuged at 13,000 rpm for 10 min at
4 °C. The supernatant was transferred to a clean tube
and evaporated under a stream of nitrogen and the ste-
roids were derivatized in to their methoximes prior to
analysis [37]. The SFC system was equipped with a
Acquity UPC2 BEH column (150 mm × 3.0 mm, 1.7 μm
particle size; Waters, Milford, MA, USA). It was kept at
40 °C and at a mobile phase flow rate of 2 mL/min. The
gradient program was started with 98% A (CO2,
99.999%) and 2% B (0.1% formic acid in methanol/iso-
propanol (1:1)), linearly increased to 17% B over 3 min,
held at 17% B for 0.5 min, followed by a linear gradient
down to 2% B over 0.5 min. Finally, it was held for 1 min
at 2% B for the elution of ionic liquids out of the instru-
ment, resulting in a total separation time of 5 min. Mass
spectrometric detection was performed using electro-
spray ionization in the positive ionization mode (ESI+)
with a capillary voltage of 2.8 kV, cone voltage of 30 V,
and source offset of 30 V. Nitrogen and argon (0.15 mL/
min) served as the desolvation gas and the collision gas,
respectively. Desolvation temperature was maintained at
500 °C. The quantification of the analytes was based on a
multiple reaction monitoring (MRM) coupled to stable
isotope dilution. The limit of quantification (LOQ) and
co-efficient of variation of steroids were 0.1–0.5 ng/mL
and 8–10%, respectively. The recovery of steroids was
more than 85%. Linear rage of the quantification for ste-
roids was 0.1–1000 ng/mL. All data was acquired, ana-
lysed and processed using the Waters MassLynx
software (version 4.1, Waters, Milford, MA, USA).
Statistical analysis
The normal prostatic volume (Vnorm) was calculated ac-
cording to Sannamwong and coworkers [38]. The for-
mula includes weight of the dogs, and is based on
healthy dogs aged 1.5–4 years: Vnorm = 0.33 * BW (kg) +
3.28. The calculated volume (V) was compared to Vnorm
to get a relative value of the prostatic size: Srel = V/Vnorm,
as previously described [4]. Dogs with a Srel > 1 thus had
a larger prostate than would be normal for dogs 4 years
or younger. Srel ≥ 2.5 was considered a clinically relevant
enlargement [4].
At baseline, the coefficient of variations (CVs) of the
volume of the prostate within a dog, when measured by
ultrasonography, was < 15% [4]. Based on this, volumes
smaller or greater than 15% compared to measurements
at baseline were defined as decreases or increases, re-
spectively, and values in between were categorized as no
significant change in volume.
A multiple regression analysis was applied to evaluate
the effect of CPSE concentrations at baseline and at
follow-up on Srel at follow-up and on the difference be-
tween Srel at baseline and at follow-up. Pearson correl-
ation was used to evaluate the correlation between the
CPSE concentration at baseline and Srel at follow-up.
Multiple regression analysis was also used to evaluate
1GE Medical LOGIQ 9 Ultrasound Imaging System, General Electric
Medical Systems, MyLab™ Alpha, Esaote SpA, Philips IE33 Ultrasound,
Philips Medical Systems
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the effect of steroid concentrations at follow-up on Srel
at follow-up and on the difference between Srel at base-
line and at follow-up. In addition, two separate models
were built, one including the steroids as the classes an-
drogens, estrogens, progestins and corticosteroids, and
the other including the ratios between the steroid clas-
ses. For the multiple regression analyses the residuals
were checked and found to be normally distributed, and
the use of multiple regression thus deemed appropriate.
Concentrations of CPSE at baseline and follow-up, as
well as volume and relative size of the prostate, were
mostly not normally distributed (evaluated using the
Ryan-Joiner test), and values are therefore presented as
median and interquartile range, IQR. Minitab (Minitab
18, Minitab Inc., State College, PA, USA) was used for
comparing V and Srel between baseline and follow-up,
after numbers had been log-transformed, using the
paired t-test. For comparison between groups with in-
creased or similar prostate size between baseline and
follow-up, the Kruskal-Wallis test was used. Fisher’s
exact test was used to compare development of clinical
signs depending on CPSE concentration or Srel at base-
line. McNemar’s test was used to compare the numbers
of dogs with cysts at baseline and at follow-up. For the
multiple regressions, R [39] was employed.
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